Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Kangpu Bio-Pharma Completes $14 Million Pre-B Round for Immuno-Modulators

publication date: Aug 9, 2019

Kangpu Bio-Pharma, a Shanghai clinical stage company, completed a $14 million Pre-B financing. Headquartered in Zhangjiang Hi-Tech Park, Kangpu is focused on developing small molecule drugs targeting immuno-modulating sites to develop treatments for cancer, autoimmune diseases and inflammation. The company has developed proprietary technologies to generate and degrade ubiquitin-protein. It also has a drug discovery combination platform called X-Synergy®. The financing was led by Shenzhen Guozhong Venture Capital and Shanghai Furong Investment. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital